In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 kick&kill clinical trial
Copyright © 2020 Rosás-Umbert, Ruiz-Riol, Fernández, Marszalek, Coll, Manzardo,Cedeño, Miró, Clotet, Hanke, Moltó, Mothe, Brander and the BCN02 study group.This is an open-access article distributed under the terms of the Creative CommonsAttribution License (CC BY). The use, distribution or reproduc...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Universitat Politècnica de Catalunya (UPC) |
| Repositorio: | UPCommons. Portal del coneixement obert de la UPC |
| Idioma: | inglés |
| OAI Identifier: | oai:upcommons.upc.edu:2117/344541 |
| Acceso en línea: | https://hdl.handle.net/2117/344541 https://dx.doi.org/10.3389/fimmu.2020.00418 |
| Access Level: | acceso abierto |
| Palabra clave: | HDAC inhibitor Kick&kill strategy Latency reversing agent (LRA) Romidepsin Therapeutic vaccine Classificació AMS::90 Operations research, mathematical programming Àrees temàtiques de la UPC::Matemàtiques i estadística::Investigació operativa Àrees temàtiques de la UPC::Ciències de la salut::Medicina |
| Sumario: | Copyright © 2020 Rosás-Umbert, Ruiz-Riol, Fernández, Marszalek, Coll, Manzardo,Cedeño, Miró, Clotet, Hanke, Moltó, Mothe, Brander and the BCN02 study group.This is an open-access article distributed under the terms of the Creative CommonsAttribution License (CC BY). The use, distribution or reproduction in other forumsis permitted, provided the original author(s) and the copyright owner(s) are creditedand that the original publication in this journal is cited, in accordance with acceptedacademic practice. No use, distribution or reproduction ispermitted which does notcomply with these terms. |
|---|